Analysis of the tissue microarray staining results revealed that, compared to EGFRvIII(−) GBM patients, the expression of MDK and CD206 was significantly upregulated in EGFRvIII(+) GBM patients, while the expression of CD86 was significantly downregulated in EGFRvIII(+) GBM patients (Fig. 2B). This evidence concerns the gene CD86 and glioblastoma.